POB4 USING CLAIMS DATA TO UNDERSTAND THE COSTS OF DIFFERENT HEALTH STATES FOR PATIENTS WITH CARDIOMETABOLIC RISK  by Mangiapane, S et al.
A325Abstracts
Cardiometabolic risk factors such as type 2 diabetes or dyslipi-
daemia have become an increasing problem in the developed
countries. Rimonabant 20 mg is a novel treatment in conjunc-
tion with diet and exercise for obese and overweight patients
with associated cardiometabolic risk factors such as type 2 dia-
betes or dyslipidaemia. In the double blinded RCT RIO-Europe
(n = 1508) and RIO-Diabetes (n = 1047), rimonabant was shown
to improve weight, waist circumference, HDL-cholesterol, TG,
HbA1c and other cardiometabolic risk factors in overweight and
obese patients with or without T2DM. The study inclusion cri-
teria correspond to Danish treatment guidelines. OBJECTIVE:
To analyse the cost-effectiveness of rimonabant as a supplement
to diet and exercise in a Danish setting. METHODS: A Markov
model (RAINBOW), evaluating scenarios of 2 and 10 years of
treatment in a Danish setting, was used to evaluate cost-effec-
tiveness based on the RIO-Europe and RIO-Diabetes study.
Modelled outcomes were cost per QALY and LYG. Danish cost
and epidemiological data were applied. RESULTS: Depending on
the treatment length (2 or 10 years) and whether the patients
were obese with or without diabetes, the cost per QALY gained
was between €11,182 and €13,164, while the cost per LYG was
between €13,734 and €39,004. These ratios are within the limits
which are normally considered to be cost-effective. CONCLU-
SIONS: Rimonabant in conjunction with diet and exercise can
be a in overweight or obese patients with dyslipidaemia or type
2 diabetes.
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OBJECTIVES: Abdominal obesity is a major risk factor for car-
diovascular disease (CVD), diabetes, and related mortality. Little
information is available on the economic burden of abdominal
obesity. Therefore, the objective of this study was to assess the
current medical resource use in patients with abdominal obesity
in Belgium. METHODS: Data on resource utilization was ret-
rospectively (1/8/2004–31/7/2005) collected by general practi-
tioners (GP) in patients aged ≥45 with abdominal obesity and
with either a history of CVD- or diabetes, or either >=2 CVD
risk factors (hypertension, dyslipidemia, impaired glucose toler-
ance). GPs were selected based on setting (urban-rural) and geo-
graphical region (north-south). Cost analysis was performed for
the whole sample, and for 2 subpopulations: patients with a
history of CVD or diabetes (64%) and patients without a CVD-
history or diabetes. Both costs related and not related to obesity
were included. The perspective of the health care payer was
taken. RESULTS: 403 patients were studied. Mean age was 61.2
(St.Err. 0.5), females represented 65.26% of the patients. The
overall cost per year for the entire sample was €1758 (St.Err.
€129) including all costs related and not related to obesity.
Excluding the costs not related to obesity the yearly cost was
€995 (St.Err. €90). For the group of patients with a history of
CVD or diabetes these costs were €2109 (St.Err. €182) and
€1252 (St.Err. €130) respectively. For the subgroup of patients
without a history of CVD nor diabetes these costs were €1099
(St.Err. €138) and €534 (St.Err. €82). CONCLUSIONS: This ret-
rospective chart review shows that patients with abdominal
obesity have a considerable cost, especially in the presence of
CVD or diabetes but also if multiple cardiovascular and/or meta-
bolic risk factors are present. Fifty-seven percent of the total cost
of care is related to the patient’s obesity.
POB4
USING CLAIMS DATA TO UNDERSTAND THE COSTS OF
DIFFERENT HEALTH STATES FOR PATIENTS WITH
CARDIOMETABOLIC RISK
Mangiapane S1, Gothe H1, Schiffhorst G1,Aidelsburger P2,
Fuchs SM2,Wasem J3, Glaeske G4, Häussler B1
1IGES GmbH, Berlin, Germany, 2Carem GmbH, Sauerlach, Germany,
3University of Duisburg-Essen, Essen, Germany, 4ZeS, Centre of Social
Policy Research, Faculty 11: Human and Health Sciences, University of
Bremen, Bremen, Germany
OBJECTIVES: In order to evaluate the costs of different health
states for patients with cardiometabolic risk, a study was per-
formed to operationalize these health states, to identify individ-
uals from a claims database and assign them to the health states.
METHODS: Claims data of a German sickness fund with 1.5
million beneﬁciaries were used for the years 2000 to 2004. Only
patients aged 18–80 years were included who were continuously
covered by the health insurance during this period. Health 
states were composed of different attributes (diabetes mellitus
with/without micro- or macrovascular complication, hyperten-
sion, hypercholesteremia, hypertriglyceridemia, coronary heart
disease, obesity), each of them being transposed into appropri-
ate ATC codes or ICD-10 codes (inpatient, outpatient, sick leave
diagnosis). Patients were selected from the database according to
their health state pattern. RESULTS: Out of n = 774,132 bene-
ﬁciaries (62% male), n = 736,653 (95%) could be assigned to
one of the deﬁned health states. Most of them (58%) were allo-
cated to the health state without any of the deﬁned attributes.
27% had 1 to 4 cardiometabolic risk factors, but no diabetes.
Four percent had no diabetes, but had already experienced car-
diovascular diseases such as myocardial infarction and/or stroke.
6% matched one of the diabetes related health states. CON-
CLUSION: Typical limitations of any analysis performed on the
basis of claims data should be borne in mind. These comprise
lack of diagnostic accuracy and incomplete knowledge of the
patients’ case histories and clinical measures for severity of
illness. Nonetheless, claims data provide useful information for
economic modelling, as they derive from a naturalistic setting
and allow an unbiased view on health care delivery and utiliza-
tion under real-life conditions. This can determine the authen-
ticity of economic models.
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OBJECTIVES: Obesity is a major risk factor for type 2 diabetes,
cardiovascular disease and stroke. Moderate weight loss of
5–10% is proven to be beneﬁcial, but often difﬁcult to achieve
with diet/exercise alone. The addition of sibutramine can reduce
and maintain weight loss through increased satiety and enhanced
resting metabolic rate. This study reviews the safety, efﬁcacy 
and cost-effectiveness of sibutramine with diet/exercise in obese
patients. METHODS: A patient level analysis was conducted of
23 RCTs of sibutramine with diet/exercise compared with
diet/exercise alone. Dichotomous outcomes (proportion of
patients losing ≥5% body weight) and multivariate risk factor-
adjusted continuous means (BMI, SBP/DBP, HbA1c and lipids)
were calculated. Least squares regression models were developed
to determine the relationship between BMI change and cardio-
